Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recentin in Recurrent Small Cell Lung Cancer
NCT00245063Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Mar 2006; status: completed.
02
Drugs
cediranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00245063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245063.